Citigroup Inc. decreased its holdings in Avantor, Inc. (NYSE:AVTR – Free Report) by 8.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 421,064 shares of the company’s stock after selling 38,691 shares during the period. Citigroup Inc. owned approximately 0.06% of Avantor worth $10,893,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Intech Investment Management LLC boosted its position in Avantor by 1.8% during the 2nd quarter. Intech Investment Management LLC now owns 29,068 shares of the company’s stock worth $616,000 after purchasing an additional 514 shares during the period. Arizona State Retirement System lifted its position in Avantor by 0.3% during the 2nd quarter. Arizona State Retirement System now owns 186,567 shares of the company’s stock worth $3,955,000 after acquiring an additional 528 shares in the last quarter. Veracity Capital LLC boosted its holdings in Avantor by 1.0% in the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after acquiring an additional 543 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Avantor by 2.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock valued at $571,000 after purchasing an additional 733 shares during the period. Finally, US Bancorp DE lifted its position in shares of Avantor by 6.2% during the third quarter. US Bancorp DE now owns 12,615 shares of the company’s stock worth $326,000 after purchasing an additional 734 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
AVTR has been the topic of a number of recent analyst reports. Wells Fargo & Company cut their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Barclays dropped their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. UBS Group reduced their target price on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.57.
Insider Buying and Selling at Avantor
In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This represents a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by company insiders.
Avantor Stock Up 0.1 %
Avantor stock opened at $21.04 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00. The company has a 50-day simple moving average of $23.40 and a 200-day simple moving average of $23.76. The firm has a market capitalization of $14.32 billion, a P/E ratio of 45.74, a P/E/G ratio of 2.56 and a beta of 1.35.
Avantor Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Featured Stories
- Five stocks we like better than Avantor
- Stock Splits, Do They Really Impact Investors?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- 3 Tickers Leading a Meme Stock Revival
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Insider Buying Explained: What Investors Need to Know
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.